DoW Peer Reviewed Medical, Clinical Trial Award
About
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have significant impact on the treatment and management of a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas and FY26 PRMRP strategic goals. Distinctive Features: Must support a clinical trial. Supports two different application categories, based on the phase of planning for the clinical trial: Clinical Trial Only or Clinical Trial with Planning Phase. The Clinical Trial with Planning Phase option is intended to support the final phase of regulatory activities and planning activities that are necessary to be completed prior to initiation of the clinical trial. The planning phase cannot be used to finalize the intervention or support animal studies. Applications that already have regulatory approvals in place and are submitting to the Clinical Trial Only option may be prioritized over those requesting the Planning Phase option. Animal studies are not supported. Studies must complete all preclinical empirical laboratory work prior to the award start date. Supports three funding levels, each offered with and without a Planning Phase: Funding Level 1: Supports phase 0 or phase 1 clinical trials or non-phased trials with fewer than 100 participants. Funding Level 2: Supports phase 2 clinical trials or non-phased trials with fewer than 300 participants. Funding.
The DoW Peer Reviewed Medical, Clinical Trial Award is designed for researchers and medical institutions ready to launch clinical trials that can significantly impact disease treatment and management. This federal grant supports the rapid implementation of clinical studies addressing congressionally directed research priorities in the Fiscal Year 2026 Peer Reviewed Medical Research Program (PRMRP). The award is ideal for teams with promising medical interventions moving from preclinical research to human testing phases. Applicants can choose between two application categories: Clinical Trial Only (for those with existing regulatory approvals) or Clinical Trial with Planning Phase (for those needing final regulatory activities and planning support before trial initiation). The program offers three distinct funding levels corresponding to different trial phases—from Phase 0 and Phase 1 trials with fewer than 100 participants, to Phase 2 trials with up to 300 participants. Researchers should apply if they have completed all preclinical laboratory work, possess a well-designed clinical protocol, and aim to advance medical innovation through rigorous human testing. This award represents a significant opportunity for medical professionals and organizations committed to accelerating clinical research that addresses critical health challenges.
Funding Facts
● Applications openDeadline
September 22, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by funding level and application cycle
Deadline
2026-09-22
Grant Type
federal
Application Cycle
Annual (FY2026 deadline: September 22, 2026)
Best For
Medical researchers, clinical research institutions, and healthcare organizations with Phase 0, Phase 1, or Phase 2 clinical trials ready for implementation
Frequently Asked Questions
Who is eligible for DoW Peer Reviewed Medical, Clinical Trial Award?
Eligibility criteria are not fully specified in available information. Applicants must have completed all preclinical empirical laboratory work prior to the award start date and be prepared to conduct a clinical trial in one of the congressionally directed FY26 PRMRP topic areas. For detailed eligibility requirements, including institutional and researcher qualifications, visit the official Department of War (DoW) PRMRP website or the grants portal.
How much funding does DoW Peer Reviewed Medical, Clinical Trial Award provide?
Specific funding amounts are not provided in available information. The program offers three funding levels based on the clinical trial phase and participant population size. Funding Level 1 supports Phase 0 or Phase 1 trials or non-phased trials with fewer than 100 participants. Funding Level 2 supports Phase 2 trials or non-phased trials with fewer than 300 participants. For exact funding ranges for FY2026, consult the official PRMRP solicitation documents.
How do I apply for DoW Peer Reviewed Medical, Clinical Trial Award?
Applications are submitted through the official DoW PRMRP application portal. You must select one of two application categories: Clinical Trial Only or Clinical Trial with Planning Phase. Choose the funding level appropriate to your trial phase and participant population. All preclinical work must be completed before the award start date. For step-by-step application instructions, required documentation, and submission guidelines, visit the official DoW grants website and review the FY2026 PRMRP solicitation announcement.
What can DoW Peer Reviewed Medical, Clinical Trial Award funding be used for?
Funding supports rapid implementation of clinical trials addressing FY26 PRMRP topic areas and strategic goals. The award covers Clinical Trial Only activities or Clinical Trial with Planning Phase activities (including final regulatory approvals and pre-trial planning). Importantly, the award does NOT support animal studies, finalization of interventions, or preclinical laboratory work. All empirical laboratory research must be completed before the award start date. Planning phase funding is limited to regulatory and trial preparation activities only.
Last updated: July 5, 2026